Enliven Therapeutics, Inc. Insider Transactions
Purchase
Sell
Enliven Therapeutics, Inc. Insider Trades History
| Insider Name | Buy/Sell | Shares Bought/Sold @ Price |
Total Transaction | Shares Held After Transaction |
Transaction Date | Filing Date | Details |
|---|---|---|---|---|---|---|---|
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 3,756 @ $17.81 | $66.89 K | 319,554 | 04/07/2025 | 04/09/2025 | |
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 2,763 @ $18.29 | $50.53 K | 316,791 | 04/07/2025 | 04/09/2025 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 3,250 @ $21.33 | $69.32 K | 23,000 | 03/27/2025 | 03/31/2025 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 1,000 @ $22.50 | $22.51 K | 23,000 | 03/24/2025 | 03/26/2025 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 12,500 @ $20.61 | $257.58 K | 1,002,688 | 03/19/2025 | 03/21/2025 | |
|
Kintz Samuel
CEO |
Sell | 12,500 @ $20.83 | $260.32 K | 990,392 | 03/17/2025 | 03/19/2025 | |
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 6,667 @ $21.44 | $142.94 K | 323,310 | 03/07/2025 | 03/11/2025 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 3,250 @ $20.41 | $66.33 K | 13,000 | 02/27/2025 | 03/03/2025 | |
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 6,667 @ $21.93 | $146.21 K | 329,977 | 02/07/2025 | 02/10/2025 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 1,000 @ $22.52 | $22.52 K | 13,000 | 02/05/2025 | 02/07/2025 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 3,250 @ $21.59 | $70.18 K | 13,000 | 01/27/2025 | 01/29/2025 | |
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 6,577 @ $24.17 | $158.96 K | 336,734 | 01/07/2025 | 01/10/2025 | |
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 90 @ $24.60 | $2.21 K | 336,644 | 01/07/2025 | 01/10/2025 | |
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 20,260 @ $24.15 | $489.33 K | 1,440 | 01/07/2025 | 01/10/2025 | |
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 1,440 @ $24.56 | $35.37 K | 0 | 01/07/2025 | 01/10/2025 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 1,000 @ $25.04 | $25.04 K | 13,000 | 01/03/2025 | 01/07/2025 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 900 @ $22.51 | $20.26 K | 0 | 12/30/2024 | 12/31/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 3,350 @ $22.15 | $74.22 K | 0 | 12/27/2024 | 12/31/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 4,250 @ $24.78 | $105.31 K | 1,000 | 11/27/2024 | 12/02/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 1,000 @ $25.38 | $25.38 K | 0 | 11/27/2024 | 12/02/2024 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Enliven Therapeutics, Inc. FAQ's
The list of insiders at Enliven Therapeutics, Inc. includes Lyssikatos Joseph P, Kintz Samuel, Hohl Benjamin, Heyman Richard A., Ballal Rahul D., Patel Anish, Collins Helen Louise.
Insiders have sold a total of 311.25 K Enliven Therapeutics, Inc. shares in the last 12 months for a total of 7.50 M sold.
The following insiders have sold Enliven Therapeutics, Inc. shares in the last 12 months: Lyssikatos Joseph P ($2.48 M), Kintz Samuel ($2.02 M), Hohl Benjamin ($1.15 M), Heyman Richard A. ($159.95 K), Ballal Rahul D. ($293.56 K), Patel Anish ($1.37 M), Collins Helen Louise ($24.48 K),